Psychedelics such as DMT, LSD, and psilocybin, which act as potent 5-hydroxytryptamine agonists, enhance neural plasticity by activating serotoninergic and glutamatergic systems and modulate signaling pathways in Alzheimer's disease, including brain-derived neurotrophic factor signaling and subsequent activation of mammalian target of rapamycin and autophagy regulators. These compounds show potential for mitigating effects of Alzheimer's disease-related dementia, which lacks a definitive cure. Controlled, dose-dependent administration represents a novel therapeutic intervention, though further studies are needed to establish long-term safety, efficacy, and optimal protocols.
Psychedelics such as DMT, LSD, and psilocybin, traditionally linked to recreational and spiritual use, are being investigated for therapeutic benefits in Alzheimer's disease-related dementia. These compounds act as serotonin agonists and enhance neural plasticity through serotonin and glutamate systems. They may modulate Alzheimer's-related signaling pathways, including the BDNF pathway, mTOR activation, and autophagy regulators. Controlled administration, depending on dosage, offers a potential novel intervention for dementia. The review highlights promising pathways but emphasizes the need for further studies to establish long-term safety, efficacy, and optimal treatment protocols.